{
    "clinical_study": {
        "@rank": "99199", 
        "acronym": "JPI-289", 
        "arm_group": [
            {
                "arm_group_label": "JPI-289", 
                "arm_group_type": "Experimental", 
                "description": "Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study in to evaluate safety, tolerability, pharmacokinetics of JPI-289\n      in healthy male subjects."
        }, 
        "brief_title": "The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "tPA treatment should be used within 3 hours after stroke onset for treating efficacy, but\n      JPI-289 treatment(PARP-1 inhibitor) showed treating efficacy more than 10 hours after stroke\n      onset. PARP-1 inhibitor add-on therapy of tPA will be very useful to prevent social,\n      economic loss from physical, and mental disable by stroke.\n\n      This clinical trial progresses to explore safety, tolerability,\n      pharmacokinetic/pharmacodynamic properties of JPI-289 by single dose escalation(7cohort).\n      Investigational product medication of each level within 4 weeks evaluate safety and\n      tolerability of patient through Data Safety Monitoring Board(DSMB) which is composed of more\n      than 3 experts except principal investigator until the last visit. In each level 6 patients\n      for investigational product and 2 patients for placebo will be allocated respectively in\n      double blind manner."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  19~55 years healthy male\n\n          -  BMI measurement 20kg/m\u00b2~27kg/m\u00b2\n\n          -  90 \u2264 SBP\uff1c140(mmHg) 60 \u2264 DBP\uff1c100(mmHg) 45 \u2264 Pulse rate\uff1c100(bpm)\n\n          -  Signed the informed consent from to participate voluntarily and to comply with the\n             trial requirements\n\n          -  For a follow-up visit and during the study period, blood samples and availability\n\n        Exclusion Criteria:\n\n          -  History of clinically significant hepatic, gastrointestinal, pulmonary,\n             musculoskeletal, endocrine, psychiatric, hematoncologic, cardiovascular (Specially\n             asthma, obstructive pulmonary disease, peptic ulcer)\n\n          -  History of skin disease of graft affecting absorption of the drug\n\n          -  History of drug abuse\n\n          -  Positive urine drug screening\n\n          -  Administrated investigational product in a previous clinical trial within 60 days of\n             the screening test\n\n          -  Donated blood within 60 days prior to screening test"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983358", 
            "org_study_id": "JP-NC-P1-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "JPI-289", 
                "description": "PARP-1 inhibitor", 
                "intervention_name": "JPI-289", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "PARP-1 inhibitor", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "mdlhslim@gmail.com", 
                "last_name": "Hyeong-Seok Lim, M.D.,Ph.D.", 
                "phone": "82-2-3010-4613"
            }, 
            "contact_backup": {
                "email": "bestdoctor@amc.seoul.kr", 
                "last_name": "Yo-Han Kim, M.D.", 
                "phone": "82-2-3010-4614"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Song-Pa Gu", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Hyeong-Seok Lim, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.", 
        "other_outcome": {
            "description": "-Blood 0h(pre-dose),1h, 4h, 7h, 24h, 48h", 
            "measure": "Difference of PAR level in PBMC between JPI-289 group and placebo group", 
            "safety_issue": "Yes", 
            "time_frame": "0h(pre-dose)~48h, 6 points"
        }, 
        "overall_contact": {
            "email": "mdlhs@gmail.com", 
            "last_name": "Hyeong-Seok Lim, M.D.,Ph.D.", 
            "phone": "82-2-3010-4613"
        }, 
        "overall_official": {
            "affiliation": "AIDS Malignancy Clinical Trials Consortium", 
            "last_name": "HyeongSeok Lim, M.D.,Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Difference of ECG, vital sign and diagnotic test in JPI-289 group and placebo group", 
            "safety_issue": "Yes", 
            "time_frame": "-21d~9d"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Blood\nUrine 0h(pre-dose), 5min, 10min, 20min, 30min(before termination of infusion JPI-289), 45min, 1h, 2h, 4h, 8h, 12h, 24h, 48h", 
            "measure": "Difference of consentration of JPI-289 in Plasma between JPI-289 group and placebo group", 
            "safety_issue": "Yes", 
            "time_frame": "0h~48h , 15 points"
        }, 
        "source": "Jeil Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jeil Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}